The current status of adjuvant treatment for high-risk renal cell carcinoma

被引：0
|
作者：
Hizal, Mutlu [1 ]
Sendur, Mehmet A. N. [1 ]
Bilgin, Burak [1 ]
Akinci, Muhammed Bulent [1 ]
Dede, Didem Sener [1 ]
Yalcin, Bulent [1 ]
机构：
[1] Yildirim Beyazit Univ, Dept Med Oncol, Ankara, Turkey
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 23期
关键词：
renal cell carcinoma; adjuvant treatment; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITORS; SUNITINIB; THERAPY;
D O I：
10.2217/fon-2017-0352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2017 / 2020
页数：4
相关论文
共 50 条
  • [21] Commentary on: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy
    Struss, Werner J.
    Black, Peter C.
    UROLOGY, 2017, 105 : 13 - 13
  • [22] Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy
    Salmasi, Amirali
    Faiena, Izak
    Drakaki, Alexandra
    Pantuck, Allan J.
    EUROPEAN UROLOGY, 2018, 74 (01) : 119 - 121
  • [23] Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions
    Kazarian, Austin G.
    Chawla, Neal S.
    Muddasani, Ramya
    Pal, Sumanta K.
    KIDNEY CANCER, 2021, 5 (01) : 9 - 20
  • [24] Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy
    Laukhtina, Ekaterina
    Quhal, Fahad
    Mori, Keiichiro
    Motlagh, Reza Sari
    Rajwa, Pawel
    Yanagisawa, Takafumi
    Mostafaei, Hadi
    Konig, Frederik
    Aydh, Abdulmajeed
    Pradere, Benjamin
    Enikeev, Dmitry
    Karakiewicz, Pierre, I
    Schmidinger, Manuela
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (01): : 120 - 124
  • [25] Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma
    Kapoor, A.
    Gharajeh, A.
    Sheikh, A.
    Pinthus, J.
    CURRENT ONCOLOGY, 2009, 16 : S62 - S68
  • [26] Adjuvant Treatment for High-Risk Clear Cell Renal Cancer Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
    Haas, Naomi B.
    Manola, Judith
    Dutcher, Janice P.
    Flaherty, Keith T.
    Uzzo, Robert G.
    Atkins, Michael B.
    DiPaola, Robert S.
    Choueiri, Toni K.
    JAMA ONCOLOGY, 2017, 3 (09) : 1249 - 1252
  • [27] Lecture 1: Current status of neoadjuvant and adjuvant treatments for renal cell carcinoma
    Kanayama, Hiro-omi
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (05) : 402 - 403
  • [28] Editorial on "Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial"
    Santoni, Matteo
    Conti, Alessandro
    Montironi, Rodolfo
    Battelli, Nicola
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S74 - S76
  • [29] EVEREST: Attempting the Summit with Adjuvant Everolimus To Treat High-risk Renal Cell Carcinoma After Surgery
    Bedke, Jens
    Bex, Axel
    EUROPEAN UROLOGY, 2024, 86 (03) : 265 - 267
  • [30] High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
    Fallara, Giuseppe
    Bandini, Marco
    Larcher, Alessandro
    Pederzoli, Filippo
    Karakiewicz, Pierre
    Tian, Zhe
    Briganti, Alberto
    Necchi, Andrea
    Salonia, Andrea
    Bertini, Roberto
    Montorsi, Francesco
    Bex, Axel
    Capitanio, Umberto
    CURRENT PROBLEMS IN CANCER, 2021, 45 (06)
12345